Lobular carcinoma in situ (LCIS) is not treated like a typical breast cancer because it isn’t one. It’s a finding that signals an increased risk of developing invasive breast cancer in the future, and management focuses on reducing that risk through medication, close monitoring, or in some cases, surgery. The approach depends on the specific type of LCIS found and your individual risk profile.
Why LCIS Is Managed Differently Than Cancer
Despite the word “carcinoma” in its name, classic LCIS is considered a risk factor rather than a malignancy. The abnormal cells found in the breast lobules rarely spread on their own, but their presence means you’re at higher risk of developing invasive breast cancer in either breast over the coming years. Because of this, the goal isn’t to eliminate a tumor. It’s to lower your future risk and catch any cancer early if it does develop.
That said, not all LCIS is the same. There are subtypes that behave more aggressively and require a different, more hands-on approach.
Risk-Reducing Medication
The National Comprehensive Cancer Network strongly recommends that women with LCIS take a risk-reducing drug. Tamoxifen is the most established option and reduces the risk of developing invasive breast cancer by about 56% in women with a history of LCIS, based on data from national chemoprevention trials. It works by blocking the effects of estrogen on breast tissue, which slows the growth of hormone-sensitive cells.
For postmenopausal women, aromatase inhibitors are another option. These drugs lower estrogen levels throughout the body rather than blocking estrogen at the cell. In a large randomized trial, one aromatase inhibitor significantly reduced the occurrence of breast abnormalities compared to placebo in high-risk postmenopausal women, including those with LCIS.
These medications are typically taken for five years. They come with their own side effects, including hot flashes, joint pain, and a small increase in certain other health risks, so the decision is a tradeoff between cancer risk reduction and quality of life. This is where the conversation with your care team matters most.
Enhanced Screening and Monitoring
Regardless of whether you take medication, close surveillance is a core part of managing LCIS. The American Cancer Society recommends yearly mammograms for women with LCIS. NCCN guidelines are more detailed: for women with LCIS whose lifetime risk of invasive breast cancer reaches 20% or higher, they recommend a clinical breast exam every 6 to 12 months, annual mammography with tomosynthesis starting at age 30, and a discussion about adding annual breast MRI starting at age 25.
Many doctors stagger these imaging tests so that you’re getting either a mammogram or an MRI every six months, rather than both at once. This alternating schedule means any changes in breast tissue are more likely to be caught early. Surveillance typically continues indefinitely, as the elevated risk from LCIS persists over time.
When Surgery Is Part of the Plan
For classic LCIS, surgery is generally not needed. Medication combined with enhanced screening is the preferred strategy, and research supports this: a study comparing outcomes in LCIS patients found that breast cancer-specific mortality was extremely low regardless of whether patients had partial mastectomy or bilateral prophylactic mastectomy. Survival outcomes for women who had a partial procedure without radiation were not inferior to those who had both breasts removed. Aggressive prophylactic surgery is not recommended for most patients with classic LCIS.
Some women with very high anxiety about future cancer risk or with strong family histories may still choose bilateral mastectomy after thorough counseling, but the data suggests this doesn’t improve survival over less aggressive approaches.
Pleomorphic and Florid LCIS: A Different Approach
Not all LCIS behaves the same way. Pleomorphic LCIS (PLCIS) and florid LCIS with significant cellular abnormalities are more concerning subtypes. Under the microscope, pleomorphic LCIS shows larger, more irregular cells with a higher rate of cell division compared to classic LCIS. Some cases also show features associated with more aggressive cancers, such as weaker hormone receptor expression.
These subtypes are managed more like ductal carcinoma in situ (DCIS), which means surgical excision with clear margins and often radiation therapy afterward. The reason for this more aggressive approach is practical: when pleomorphic LCIS is found on a core needle biopsy, about 20% of patients are found to have invasive cancer when the full tissue is surgically removed. That upgrade rate is high enough to make surgery a standard recommendation.
In a study of patients treated surgically for pleomorphic LCIS, outcomes were excellent when margins were clear of abnormal cells. Seven patients had mastectomy and eleven had lumpectomy, with only one invasive recurrence observed in the group.
What Happens After a Core Needle Biopsy
If LCIS is found on a core needle biopsy, the next step depends on what the pathologist sees. Classic LCIS that matches what imaging suggested (concordant with the imaging findings) can often be monitored without further surgery. But several features on biopsy push toward surgical excision:
- Pleomorphic or florid LCIS with significant nuclear abnormalities warrants surgical removal with clear margins
- High degree of atypia or necrosis (dead cells within the tissue) on the biopsy sample favors a full surgical evaluation
- Multiple foci of LCIS involving four or more terminal ductal units on the core biopsy is associated with a higher risk of underlying malignancy and calls for excisional biopsy
- Non-concordant findings, where the LCIS doesn’t explain what was seen on imaging, also require surgical excision to rule out a more serious diagnosis
The purpose of surgical excision in these situations isn’t to treat LCIS itself. It’s to make sure nothing more serious is hiding in the surrounding tissue that the biopsy needle missed.
Putting the Pieces Together
For most women diagnosed with classic LCIS, the management plan combines two elements: a risk-reducing medication taken for several years and a long-term screening schedule that alternates between mammography and MRI. This combination addresses both sides of the equation, actively lowering the chance that invasive cancer develops while maintaining close enough surveillance to detect it early if it does.
For the less common pleomorphic or florid subtypes, surgical excision with clear margins is the standard first step, sometimes followed by radiation. After that, the same risk-reduction and monitoring strategies apply. The subtype matters significantly in determining how your care team approaches the initial finding, so understanding which type of LCIS you have is one of the most important questions to ask after diagnosis.